Evaluation of commercial assays for the assessment of SARS-CoV-2 antibody response in hemodialysis patients
Description
CONCLUSIONS: There is high concordance between commercial SARS-CoV-2 serological assays and SARS-CoV-2 serological assays developed in Canada. Hemodialysis patients exhibited varying immunogenicity following two doses of the COVID-19 mRNA vaccine
